Decellularized Descemet's Membrane for Limbal Stem Cell Transplants
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for limbal stem cell deficiency, such as keratolimbal allografts, simple limbal epithelial transplants, and cultured limbal transplants, are limited by high rejection rates, resource constraints, and suboptimal long-term success due to the use of amniotic membrane, which is opaque and unstable on the ocular surface, and lack of a suitable substrate for maintaining stem cell viability and phenotype.
Innovation Solution
The use of decellularized and isolated Descemet's membrane as a substrate for culturing and transplanting limbal stem cells, which mimics the limbal niche microenvironment, promoting proliferation and maintaining stem cell phenotype, and is transparent and resistant to collagenase digestion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If amniotic membrane is used as a substrate for limbal stem cell transplantation, then stem cell viability is maintained, but the membrane is opaque and unstable on the ocular surface
Solution Approach 1:
The patent extracts the essential function of amniotic membrane (providing a viable substrate for stem cells) while removing its detrimental properties (opacity and instability). This is achieved by using decellularized Descemet's membrane as an alternative substrate that provides necessary structural support and biochemical cues for stem cell viability while being transparent and stable on the ocular surface.
Solution Approach 2:
The patent changes the physical and chemical parameters of the substrate material by using decellularized Descemet's membrane instead of amniotic membrane. This material transformation maintains the biochemical properties necessary for stem cell survival while improving optical transparency and mechanical stability on the ocular surface.
2Reliability
If keratolimbal allografts are performed, then limbal stem cell deficiency is treated, but rejection rates are high
Solution Approach 1:
The patent removes the immunogenic components (cellular elements) from the transplant material by using decellularized Descemet's membrane. This extraction of cellular material eliminates the primary target for immune recognition while preserving the extracellular matrix structure that provides structural support and biochemical signals necessary for stem cell regeneration.
Solution Approach 2:
The patent converts the potential harm of immune rejection into a benefit by using decellularization to create an acellular matrix. The decellularized material serves as an immunologically privileged scaffold that promotes stem cell regeneration without triggering rejection, effectively transforming a harmful immune response into a beneficial regenerative process.
3Illumination intensity
If Descemet's membrane is used as a substrate, then transparency and collagenase resistance are achieved, but endothelium must be removed
Solution Approach 1:
The patent extracts the endothelial cell layer from Descemet's membrane to create a decellularized substrate. This removal of the endothelium eliminates cellular interference with optical transparency while the remaining extracellular matrix provides structural integrity and biochemical cues for limbal stem cell attachment and proliferation.
Data Source
AI summary
This disclosure describes methods of preparing a decellularized Descemet's membrane and an isolated Descemet's membrane, methods of using an isolated Descemet's membrane, and tissues prepared using an isolated Descemet's membrane. This disclosure further describes a composition that includes an isolated Descemet's membrane. In some embodiments, the tissues and methods described herein may be used to treat a limbal stem cell deficiency or as an ocular surface bandage.